KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
- PMID: 21163703
- DOI: 10.1016/S1470-2045(10)70209-6
KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer
Abstract
The discovery of mutant KRAS as a predictor of resistance to epidermal growth-factor receptor (EGFR) monoclonal antibodies brought a major change in the treatment of metastatic colorectal cancer. This seminal finding also highlighted our sparse knowledge about key signalling pathways in colorectal tumours. Drugs that inhibit oncogenic alterations such as phospho-MAP2K (also called MEK), phospho-AKT, and mutant B-RAF seem promising as single treatment or when given with EGFR inhibitors. However, our understanding of the precise role these potential drug targets have in colorectal tumours, and the oncogenic dependence that tumours might have on these components, has not progressed at the same rate. As a result, patient selection and prediction of treatment effects remain problematic. We review the role of mutations in genes other than KRAS on the efficacy of anti-EGFR therapy, and discuss strategies to target these oncogenic alterations alone or in combination with receptor tyrosine-kinase inhibition.
Copyright © 2011 Elsevier Ltd. All rights reserved.
Similar articles
-
The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.Acta Oncol. 2014 Jul;53(7):852-64. doi: 10.3109/0284186X.2014.895036. Epub 2014 Mar 25. Acta Oncol. 2014. PMID: 24666267 Review.
-
Promising biomarkers for predicting the outcomes of patients with KRAS wild-type metastatic colorectal cancer treated with anti-epidermal growth factor receptor monoclonal antibodies: a systematic review with meta-analysis.Int J Cancer. 2013 Oct 15;133(8):1914-25. doi: 10.1002/ijc.28153. Epub 2013 Jul 13. Int J Cancer. 2013. PMID: 23494461 Review.
-
Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer.Clin Cancer Res. 2011 Jul 15;17(14):4901-14. doi: 10.1158/1078-0432.CCR-10-3137. Epub 2011 Jun 1. Clin Cancer Res. 2011. PMID: 21632860
-
Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.Magy Onkol. 2010 Dec;54(4):383-94. doi: 10.1556/MOnkol.54.2010.4.13. Magy Onkol. 2010. PMID: 21163770
-
[Molecular predictive markers of EGFR-targeted therapy in metastatic colorectal cancer].Cesk Patol. 2011 Oct;47(4):154-8. Cesk Patol. 2011. PMID: 22145213 Review. Czech.
Cited by
-
Disruption of thioredoxin metabolism enhances the toxicity of transforming growth factor β-activated kinase 1 (TAK1) inhibition in KRAS-mutated colon cancer cells.Redox Biol. 2015 Aug;5:319-327. doi: 10.1016/j.redox.2015.06.004. Epub 2015 Jun 18. Redox Biol. 2015. PMID: 26114584 Free PMC article.
-
Immunohistochemistry Markers in Ovarian and Fallopian Tube Neoplasms: a Comprehensive Review.Indian J Surg Oncol. 2024 Sep;15(Suppl 3):465-480. doi: 10.1007/s13193-024-02049-y. Epub 2024 Jul 25. Indian J Surg Oncol. 2024. PMID: 39328739 Review.
-
Associations of SEMA7A, SEMA4D, ADAMTS10, and ADAM8 with KRAS, NRAS, BRAF, PIK3CA, and AKT Gene Mutations, Microsatellite Instability Status, and Cytokine Expression in Colorectal Cancer Tissue.Curr Issues Mol Biol. 2024 Sep 15;46(9):10218-10248. doi: 10.3390/cimb46090609. Curr Issues Mol Biol. 2024. PMID: 39329961 Free PMC article.
-
Association of KRAS, NRAS, BRAF and PIK3CA gene mutations with clinicopathological features, prognosis and ring finger protein 215 expression in patients with colorectal cancer.Biomed Rep. 2023 Oct 31;19(6):104. doi: 10.3892/br.2023.1686. eCollection 2023 Dec. Biomed Rep. 2023. PMID: 38025833 Free PMC article.
-
Biomarkers of benefit from cetuximab-based therapy in metastatic colorectal cancer: interaction of EGFR ligand expression with RAS/RAF, PIK3CA genotypes.BMC Cancer. 2013 Feb 2;13:49. doi: 10.1186/1471-2407-13-49. BMC Cancer. 2013. PMID: 23374602 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous